This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, J. C. Articles by Davies, J. S. Search for Related Content PubMed PubMed Citation Articles by Smith, J. C. Articles by Davies, J. S.

The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate Cancer

Departments of Medicine (J.C.S., L.M.E., M.F.S., J.S.D.), Urology (S.B., H.G.K.), Oncology (M.D.M.), and Cardiology (J.R.C.), University Hospital of Wales, Heath Park, Cardiff, United Kingdom CF14 4XW; and Medical Research Council Clinical Trials Unit (M.P.), London, United Kingdom NW1 2DA

Address all correspondence and requests for reprints to: Dr. Jamie C. Smith, Department of Endocrinology, 7th Floor Link Corridor, University Hospital of Wales, Heath Park, Cardiff, United Kingdom CF14 4XW. E-mail: smithjc1{at}cardiff.ac.uk

Abstract

Sex hormones appear to play a pivotal role in determining cardiovascular risk. Androgen deprivation therapy for males with prostate cancer results in a hypogonadal state that may have important, but as yet undetermined, effects on the vasculature. We studied the effects of androgen deprivation therapy on large artery stiffness in 22 prostate cancer patients (mean age, 67 ± 8 yr) over a 6-month period. Arterial stiffness was assessed using pulse-wave analysis, a technique that measures peripheral arterial pressure waveforms and generates corresponding central aortic waveforms. This allows determination of the augmentation of central pressure resulting from wave reflection and the augmentation index, a measure of large artery stiffness. Body compositional changes were assessed using bioelectrical impedance analysis. Fasting lipids, glucose, insulin, testosterone, and estradiol were measured. After a 3-month treatment period, the augmentation index increased from 24 ± 6% (mean ± SD) at baseline to 29 ± 9% (P = 0.003) despite no change in peripheral blood pressure. Timing of wave reflection was reduced from 137 ± 7 to 129 ± 10 msec (P = 0.003). Fat mass increased from 20.2 ± 9.4 to 21.9 ± 9.6 kg (P = 0.008), whereas lean body mass decreased from 63.2 ± 6.8 to 61.5 ± 6.0 kg (P = 0.016). There were no changes in lipids or glucose during treatment. Median serum insulin rose from 11.8 (range, 5.6–49.1) to 15.1 (range, 7.3–83.2) mU/liter at 1 month (P = 0.021) and to 19.3 (range, 0–85.0 mU/liter by 3 months (P = 0.020). There was a correlation between the changes in fat mass and insulin concentration over the 3-month period (r = 0.56; P = 0.013). In a subgroup of patients whose treatment was discontinued after 3 months, the augmentation index decreased from 31 ± 7% at 3 months to 29 ± 5% by 6 months, in contrast to patients receiving continuing treatment in whom the augmentation index remained elevated at 6 months compared with baseline (P = 0.043).

These data indicate that induced hypogonadism in males with prostate cancer results in a rise in the augmentation of central arterial pressure, suggesting large artery stiffening. Adverse body compositional changes associated with rising insulin concentrations suggest reduced insulin sensitivity. These adverse hemodynamic and metabolic effects may increase cardiovascular risk in this patient group.

This article has been cited by other articles:

				S. Basaria Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth J Androl, September 1, 2008; 29(5): 534 - 539. [Abstract] [Full Text] [PDF]

				M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith Management of Complications of Prostate Cancer Treatment CA Cancer J Clin, July 1, 2008; 58(4): 196 - 213. [Abstract] [Full Text] [PDF]

				S. Shahani, M. Braga-Basaria, and S. Basaria Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2042 - 2049. [Abstract] [Full Text] [PDF]

				M. R. Smith, S. B. Malkowicz, F. Chu, J. Forrest, P. Sieber, K. G. Barnette, D. Rodriquez, and M. S. Steiner Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study J. Clin. Oncol., April 10, 2008; 26(11): 1824 - 1829. [Abstract] [Full Text] [PDF]

				S. Basaria and A. S. Dobs Testosterone Making an Entry Into the Cardiometabolic World Circulation, December 4, 2007; 116(23): 2658 - 2661. [Full Text] [PDF]

				D. S. Hydock, C.-Y. Lien, C. M. Schneider, and R. Hayward Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3254 - H3264. [Abstract] [Full Text] [PDF]

				S. C Larsson and A. Wolk Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies Am. J. Clinical Nutrition, September 1, 2007; 86(3): 556 - 565. [Abstract] [Full Text] [PDF]

				M. J. Walton, N. Kumar, D. T. Baird, H. Ludlow, and R. A. Anderson 7{alpha}-Methyl-19-Nortestosterone (MENT) vs Testosterone in Combination With Etonogestrel Implants for Spermatogenic Suppression in Healthy Men J Androl, September 1, 2007; 28(5): 679 - 688. [Abstract] [Full Text] [PDF]

				R. R. Rajendran and G. D. Kao "No Turning Bax" in the Combined Battle against Prostate Cancer: Clin. Cancer Res., June 15, 2007; 13(12): 3435 - 3438. [Full Text] [PDF]

				A. V. D'Amico, J. W. Denham, J. Crook, M.-H. Chen, S. Z. Goldhaber, D. S. Lamb, D. Joseph, K.-H. Tai, S. Malone, C. Ludgate, et al. Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions J. Clin. Oncol., June 10, 2007; 25(17): 2420 - 2425. [Abstract] [Full Text] [PDF]

				S. Basaria, D. C. Muller, M. A. Carducci, J. Egan, and A. S. Dobs Relation Between Duration of Androgen Deprivation Therapy and Degree of Insulin Resistance in Men With Prostate Cancer Arch Intern Med, March 26, 2007; 167(6): 612 - 613. [Full Text] [PDF]

				A. V. D'Amico Toward the Optimal Use of Androgen Suppression Therapy in the Radiotherapeutic Management of Prostate Cancer J. Clin. Oncol., January 1, 2007; 25(1): 8 - 9. [Full Text] [PDF]

				F. Fantin, A. Mattocks, C. J. Bulpitt, W. Banya, and C. Rajkumar Is augmentation index a good measure of vascular stiffness in the elderly? Age Ageing, January 1, 2007; 36(1): 43 - 48. [Abstract] [Full Text] [PDF]

				N. L. Keating, A. J. O'Malley, and M. R. Smith Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4448 - 4456. [Abstract] [Full Text] [PDF]

				M. Braga-Basaria, A. S. Dobs, D. C. Muller, M. A. Carducci, M. John, J. Egan, and S. Basaria Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy J. Clin. Oncol., August 20, 2006; 24(24): 3979 - 3983. [Abstract] [Full Text] [PDF]

				D Kapoor, E Goodwin, K S Channer, and T H Jones Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol., June 1, 2006; 154(6): 899 - 906. [Abstract] [Full Text] [PDF]

				M. R. Smith, H. Lee, and D. M. Nathan Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1305 - 1308. [Abstract] [Full Text] [PDF]

				E. L. Ding, Y. Song, V. S. Malik, and S. Liu Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis JAMA, March 15, 2006; 295(11): 1288 - 1299. [Abstract] [Full Text] [PDF]

				V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med, February 27, 2006; 166(4): 465 - 471. [Abstract] [Full Text] [PDF]

				J. Q. Purnell, L. B. Bland, M. Garzotto, D. Lemmon, E. M. Wersinger, C. W. Ryan, J. D. Brunzell, and T. M. Beer Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer J. Lipid Res., February 1, 2006; 47(2): 349 - 355. [Abstract] [Full Text] [PDF]

				N. Pitteloud, V. K. Mootha, A. A. Dwyer, M. Hardin, H. Lee, K.-F. Eriksson, D. Tripathy, M. Yialamas, L. Groop, D. Elahi, et al. Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men Diabetes Care, July 1, 2005; 28(7): 1636 - 1642. [Abstract] [Full Text] [PDF]

				J. Nuver, A. J. Smit, B. H.R. Wolffenbuttel, W. J. Sluiter, H. J. Hoekstra, D. T. Sleijfer, and J. A. Gietema The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer J. Clin. Oncol., June 1, 2005; 23(16): 3718 - 3725. [Abstract] [Full Text] [PDF]

				T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 657 - 660. [Abstract] [Full Text] [PDF]

				S. T. Page, K. L. Herbst, J. K. Amory, A. D. Coviello, B. D. Anawalt, A. M. Matsumoto, and W. J. Bremner Testosterone Administration Suppresses Adiponectin Levels in Men J Androl, January 1, 2005; 26(1): 85 - 92. [Abstract] [Full Text] [PDF]

				E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu Testosterone replacement therapy: current trends and future directions Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419. [Abstract] [Full Text] [PDF]

				A. Lipton Toward New Horizons: The Future of Bisphosphonate Therapy Oncologist, September 1, 2004; 9(suppl_4): 38 - 47. [Abstract] [Full Text] [PDF]

				P. Szulc, F. Duboeuf, F. Marchand, and P. D Delmas Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study Am. J. Clinical Nutrition, August 1, 2004; 80(2): 496 - 503. [Abstract] [Full Text] [PDF]

				M. R. Smith, M. Goode, A. L. Zietman, F. J. McGovern, H. Lee, and J. S. Finkelstein Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition J. Clin. Oncol., July 1, 2004; 22(13): 2546 - 2553. [Abstract] [Full Text] [PDF]

				M. Muller, Y. T. van der Schouw, J. H. H. Thijssen, and D. E. Grobbee Endogenous Sex Hormones and Cardiovascular Disease in Men J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5076 - 5086. [Abstract] [Full Text] [PDF]

				P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF]

				C. Parker and D. Dearnaley Re: All-Cause Mortality in Randomized Trials of Cancer Screening J Natl Cancer Inst, June 5, 2002; 94(11): 861 - 862. [Full Text] [PDF]